Physician profile
Ashraf Sefain
NPI 1689211054
$2,347.52
in general payments reported to CMS, 2019-2025
17 companies · $981 in 2025
The $981 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,367 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.25 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $360.88 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.88 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $277.80 | 2024-2025 | Qelbree |
| Bausch Health US, LLC | $221.73 | 2024-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $209.98 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $176.25 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $160.59 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $113.06 | 2024 | |
| Collegium Pharmaceutical, INC. | $97.00 | 2025 | Jornay Pm |
| Tris Pharma INC | $95.21 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $84.60 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $62.62 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $61.92 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $47.92 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $30.97 | 2024 | Ingrezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $20.39 | 2024 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $19.72 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Sefain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.